Shiro Fujii

1.0k citations
57 papers · 577 indexed · h-index 14
Topics
Multiple Myeloma Research and Treatments (25 papers)Peptidase Inhibition and Analysis (8 papers)Cancer Mechanisms and Therapy (7 papers)
Journals
SHILAP Revista de lepidopterologíaBloodPLoS ONE

In The Last Decade

Shiro Fujii

49 papers receiving 564 citations

Peers

Shiro Fujii
Comparison fields: 5 of 88
  • Molecular Biology 259
  • Hematology 224
  • Oncology 192
  • Cancer Research 108
  • Pathology and Forensic Medicine 93
Replace Shingen Nakamura with:
Shingen Nakamura Japan
Tomoaki Wada Japan
Mikinori Miyazaki Japan
Toshiyuki Kitoh Japan
Michael Harvey Australia
Ansamma Joseph United States
Haitao Bai China
Ann Lin United States
Emily K. Thomas United States
N. J. Philpott United Kingdom
Shiro Fujii relative to Shingen Nakamura Japan Shingen Nakamura's profile →
Citations per field
00.5×1.5×
Shingen Nakamura · 1×
Citations per year

Countries citing papers authored by Shiro Fujii

Since Specialization
Citations

This map shows the geographic impact of Shiro Fujii's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shiro Fujii with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shiro Fujii more than expected).

Fields of papers citing papers by Shiro Fujii

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shiro Fujii. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shiro Fujii. The network helps show where Shiro Fujii may publish in the future.

Co-authorship network of co-authors of Shiro Fujii

This figure shows the co-authorship network connecting the top 25 collaborators of Shiro Fujii. A scholar is included among the top collaborators of Shiro Fujii based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shiro Fujii. Shiro Fujii is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 1
3 0
4 0
5 1
6 1
7 1
8 0
9 6
10 25
11 14
12 32
13 13
14 20
15 36
16 22
17 4
18 82
19 12
20 42

About Shiro Fujii

Shiro Fujii is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine, having authored 57 papers that have together received 577 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (25 papers), Peptidase Inhibition and Analysis (8 papers) and Cancer Mechanisms and Therapy (7 papers). The work is most often cited by research in Hematology (224 citations), Cancer Research (108 citations) and Oncology (192 citations). Shiro Fujii has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Masahiro Abe, Kumiko Kagawa, Hirokazu Miki, Shingen Nakamura, Takeshi Harada, Shuji Ozaki, Toshio Matsumoto, Kyoko Takeuchi, Asuka Oda and Hiroe Amou. Their work appears in journals such as SHILAP Revista de lepidopterología, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026